IN2012DN09335A - - Google Patents

Download PDF

Info

Publication number: IN2012DN09335A
Authority: IN; India
Prior art keywords: compositions; methods; synthetic retinal; retinal derivatives; retinoid
Prior art date: 2004-06-18

Application number

Other languages

English (en)

Inventor

Krzysztof Palczewski

Mathew Batten

Original Assignee

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-18

Filing date

2005-06-20

Publication date

2015-08-21

2005-06-20 Application filed by Univ Washington filed Critical Univ Washington

2015-08-21 Publication of IN2012DN09335A publication Critical patent/IN2012DN09335A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Ophthalmology & Optometry (AREA)
Physiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IN9335DEN2012 2004-06-18 2005-06-20 IN2012DN09335A (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58088904P	2004-06-18	2004-06-18
PCT/US2005/021812 WO2006002097A2 (en)	2004-06-18	2005-06-20	Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (1)

Publication Number	Publication Date
IN2012DN09335A true IN2012DN09335A (de)	2015-08-21

Family

ID=35782277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN9335DEN2012 IN2012DN09335A (de)	2004-06-18	2005-06-20

Country Status (26)

Country	Link
US (8)	US7951841B2 (de)
EP (5)	EP2397133B1 (de)
JP (2)	JP5166026B2 (de)
KR (4)	KR20140140616A (de)
CN (2)	CN1988898B (de)
AU (1)	AU2005257997B2 (de)
BR (1)	BRPI0511396B1 (de)
CA (2)	CA2571049C (de)
CY (2)	CY1114873T1 (de)
DK (2)	DK2397133T3 (de)
ES (4)	ES2752924T3 (de)
HR (1)	HRP20140116T1 (de)
HU (1)	HUE036596T2 (de)
IL (4)	IL180078A (de)
IN (1)	IN2012DN09335A (de)
LT (1)	LT2397133T (de)
MX (2)	MXPA06014750A (de)
NO (1)	NO339969B1 (de)
NZ (2)	NZ587006A (de)
PL (2)	PL1765322T3 (de)
PT (2)	PT1765322E (de)
RS (1)	RS53178B (de)
RU (2)	RU2408578C2 (de)
SI (2)	SI2397133T1 (de)
WO (1)	WO2006002097A2 (de)
ZA (1)	ZA200700368B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3326623A1 (de)	2003-03-14	2018-05-30	University of Washington	Retinoidersätze und opsinagonisten sowie verfahren zur verwendung davon
KR20140140616A (ko)	2004-06-18	2014-12-09	유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션	시각 이상 치료를 위한 레티날 유도체 및 이를 이용하기 위한 방법
PL1768657T3 (pl)	2004-06-23	2009-01-30	Revision Therapeutics Inc	Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
BRPI0520207A2 (pt) *	2004-12-08	2012-09-25	Revision Therapeutics Inc	uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
CA2657238A1 (en) *	2006-07-27	2008-01-31	University Of Florida Research Foundation, Inc.	Compositions and methods for treating or preventing ophthalmic disease
CA2657015A1 (en) *	2006-07-27	2008-01-31	University Of Florida Research Foundation, Inc.	Opsin stabilizing compounds and methods of use
WO2008063768A2 (en) *	2006-10-12	2008-05-29	Case Western Reserve University	Compositions and methods for treating metabolic diseases
WO2008131368A2 (en)	2007-04-20	2008-10-30	Acucela Inc.	Styrenyl derivative compounds for treating ophthalmic diseases and disorders
AU2015200520B2 (en) *	2008-02-11	2017-02-09	University Of Washington	Methods for the treatment and prevention of age-related retinal dysfunction
KR101810381B1 (ko)	2008-02-11	2017-12-19	유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션	연령-관련 망막 기능장애의 치료 및 예방 방법
US8529907B2 (en)	2008-04-29	2013-09-10	Nikken Sohonsha Corporation	Methods of treating ophthalmic disorders
IN2012DN00352A (de)	2009-06-16	2015-08-21	Bikam Pharmaceuticals Inc
MX2012003220A (es) *	2009-09-15	2012-08-03	Quadra Logic Tech Inc	Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
EP2509596B1 (de)	2009-12-08	2019-08-28	Case Western Reserve University	Gamma aminosäure zur behandlung von augenerkrankungen
US8889660B2 (en)	2010-01-20	2014-11-18	Case Western Reserve University	Methods for treating obesity or an obesity related condition
WO2011132084A2 (en)	2010-04-19	2011-10-27	Qlt Inc.	Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
CA2816968C (en) *	2010-11-05	2019-11-26	The Board Of Trustees Of The Leland Stanford Junior University	Optically-controlled cns dysfunction
US10226536B2 (en) *	2011-11-28	2019-03-12	Case Western Reserve University	Polysaccharide therapeutic conjugates
US20150038582A1 (en) *	2012-03-01	2015-02-05	Qlt Inc.	Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
MX389866B (es) *	2012-03-01	2025-03-20	Retinagenix LLC	El uso de 9-cis-retinil acetato para mejorar la funcion visual de un sujeto que padece de perdida de la funcion visual originada por una deficiencia retinoide endogena de 11-cis retinal.
AU2013271378A1 (en)	2012-06-07	2014-12-18	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the inhibition of Pin1
US20150119388A1 (en) *	2012-06-15	2015-04-30	The Children's Hospital Philadelphia	Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2015184453A1 (en)	2014-05-30	2015-12-03	Case Western Reserve University	Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en)	2014-06-18	2021-09-28	Case Western Reserve University	Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en)	2014-07-17	2016-01-21	Beth Israel Deaconess Medical Center, Inc.	Biomarkers for pin1-associated disorders
US10925980B2 (en)	2014-08-04	2021-02-23	Case Western Reserve University	Molecular probes and methods of use
US10548864B2 (en)	2015-03-12	2020-02-04	Beth Israel Deaconess Medical Center, Inc.	Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en)	2015-06-18	2022-08-09	Case Western Reserve University	Compositions and methods for the delivery of nucleic acids
US12060318B2 (en)	2015-10-09	2024-08-13	Case Western Reserve University	Compositions and methods for the delivery of nucleic acids
MY194096A (en) *	2016-04-28	2022-11-11	Spark Therapeutics Inc	Relative potency assay for viral vector encoding isomerhydrolases
CN118922182A (zh) *	2022-02-04	2024-11-08	纽约大学	类维生素a治疗心房颤动的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB797977A (en) *	1956-01-16	1958-07-09	Hoffmann La Roche	Vitamin-a esters and a process for the manufacture thereof
US3196048A (en)	1961-12-19	1965-07-20	Exxon Research Engineering Co	Cathode catalyst for fuel cells
US3196078A (en) *	1962-01-30	1965-07-20	Ortho Pharma Corp	Process for combating retinits pigmentosa
US3517067A (en)	1964-02-11	1970-06-23	Eastman Kodak Co	Syntheses of quaternary phosphonium salts
DE2300107C2 (de) *	1973-01-03	1982-03-11	Basf Ag, 6700 Ludwigshafen	Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) *	1974-12-03	1976-06-16	Basf Ag	4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja)	1985-05-28	1986-12-05	Taisho Pharmaceut Co Ltd	レチノイド誘導体
US5310764A (en)	1992-05-08	1994-05-10	Steven Baranowitz	Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) *	1993-06-02	1994-12-13	Lion Corp	安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (de)	1994-04-04	1997-01-22	FREEMAN, William R.	Verwendung der phosphonylmethoxyalkyl-nukleoside zur behandlung des erhöhten innenaugendrucks
RU2106843C1 (ru) *	1994-06-29	1998-03-20	Красноярская государственная медицинская академия	Способ лечения близорукости
JPH08198746A (ja)	1995-01-18	1996-08-06	Lion Corp	可溶化点眼剤
US5837728A (en)	1995-01-27	1998-11-17	Molecular Design International	9-cis retinoic acid esters and amides and uses thereof
US5489611A (en)	1995-02-10	1996-02-06	Warner-Lambert Company	Method for lowering plasma levels of lipoprotein (a)
PL322624A1 (en) *	1995-04-03	1998-02-02	Johnson & Johnson Consumer	Skin care composition containing retinoides and liposomes
US5620970A (en) *	1995-06-05	1997-04-15	Alcon Laboratories, Inc.	Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en)	1996-04-25	1998-02-10	Elizabeth Arden Co., Division Of Conopco, Inc.	Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (de)	1997-08-23	1999-04-14	Werner Bollag	Behandlung von zellvermittelten Immunkrankheiten
US6391924B1 (en)	1997-12-10	2002-05-21	Hampar Karageozian	Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en)	1998-07-16	2003-04-22	Gentrix Llc	Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en)	1999-05-06	2002-04-16	The President & Fellows Of Harvard College	Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en)	1999-08-06	2001-10-09	Alcon Universal Ltd.	Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
KR20010113918A (ko)	2000-03-10	2001-12-28	추후제출	후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물
US20020028849A1 (en)	2000-04-18	2002-03-07	Godkin James D.	Use of retinol in assisted-reproduction protocols
US6696069B2 (en)	2000-06-30	2004-02-24	Unilever Home & Personal Care Usa, Division Of Conopco, Inc.	Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
WO2002055540A1 (en)	2001-01-11	2002-07-18	Chebigen Inc.	New retinol derivatives, the method of preparations and the uses thereof
CA2435410A1 (en)	2001-01-26	2002-08-01	Steven Baranowitz	Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en)	2001-02-19	2001-04-04	King S College London	Method
CA2442670A1 (en)	2001-04-13	2002-10-24	The Trustees Of The University Of Pennsylvania	Method of treating or retarding the development of blindness
AU2003210597A1 (en) *	2002-01-18	2003-07-30	Tatton Technologies, Llc.	Methods for treating eye disorders
US20030215413A1 (en)	2002-03-22	2003-11-20	L'oreal	Compositions containing stabilized retinoid
US20040097587A1 (en)	2002-03-27	2004-05-20	Arbiser Jack L	Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CA2480047A1 (en)	2002-03-29	2003-10-09	Maxim Pharmaceuticals, Inc.	Use of rom production and release inhibitors to treat and prevent intraocular damage
EP3326623A1 (de)	2003-03-14	2018-05-30	University of Washington	Retinoidersätze und opsinagonisten sowie verfahren zur verwendung davon
US7566808B2 (en) *	2004-02-17	2009-07-28	President And Fellows Of Harvard College	Management of ophthalmologic disorders, including macular degeneration
EP1722766A2 (de)	2004-02-17	2006-11-22	President And Fellows Of Harvard College	Behandlung von augenerkrankungen einschliesslich makulardegeneration
NZ550340A (en)	2004-03-17	2010-08-27	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle using a retinoid
KR20140140616A (ko)	2004-06-18	2014-12-09	유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션	시각 이상 치료를 위한 레티날 유도체 및 이를 이용하기 위한 방법
PL1768657T3 (pl)	2004-06-23	2009-01-30	Revision Therapeutics Inc	Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
WO2006033734A2 (en)	2004-08-18	2006-03-30	Sirion Therapeutics, Inc.	Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US20080275133A1 (en)	2004-09-30	2008-11-06	University Of Calfornia-San Francisco	Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation
EP2687208A1 (de)	2007-09-12	2014-01-22	The Trustees of Columbia University in the City of New York	Zusammensetzungen und Verfahren zur Behandlung von Makuladegeneration
KR101810381B1 (ko)	2008-02-11	2017-12-19	유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션	연령-관련 망막 기능장애의 치료 및 예방 방법

2005
- 2005-06-20 KR KR1020147030120A patent/KR20140140616A/ko not_active Ceased
- 2005-06-20 PL PL05773576T patent/PL1765322T3/pl unknown
- 2005-06-20 DK DK11163947.2T patent/DK2397133T3/en active
- 2005-06-20 DK DK05773576.3T patent/DK1765322T3/da active
- 2005-06-20 LT LTEP11163947.2T patent/LT2397133T/lt unknown
- 2005-06-20 ZA ZA200700368A patent/ZA200700368B/xx unknown
- 2005-06-20 EP EP11163947.2A patent/EP2397133B1/de not_active Expired - Lifetime
- 2005-06-20 EP EP05773576.3A patent/EP1765322B1/de not_active Expired - Lifetime
- 2005-06-20 ES ES11163940T patent/ES2752924T3/es not_active Expired - Lifetime
- 2005-06-20 HR HRP20140116TT patent/HRP20140116T1/hr unknown
- 2005-06-20 KR KR1020137016276A patent/KR101490145B1/ko not_active Expired - Fee Related
- 2005-06-20 RU RU2007101735/04A patent/RU2408578C2/ru active
- 2005-06-20 RS RS20140036A patent/RS53178B/sr unknown
- 2005-06-20 SI SI200532176T patent/SI2397133T1/sl unknown
- 2005-06-20 BR BRPI0511396-2A patent/BRPI0511396B1/pt not_active IP Right Cessation
- 2005-06-20 CN CN2005800240983A patent/CN1988898B/zh not_active Expired - Fee Related
- 2005-06-20 EP EP11163943.1A patent/EP2397132B1/de not_active Expired - Lifetime
- 2005-06-20 EP EP11163940.7A patent/EP2397131B1/de not_active Expired - Lifetime
- 2005-06-20 EP EP11163939.9A patent/EP2397130B1/de not_active Expired - Lifetime
- 2005-06-20 MX MXPA06014750A patent/MXPA06014750A/es active IP Right Grant
- 2005-06-20 KR KR1020077001074A patent/KR101337321B1/ko not_active Expired - Fee Related
- 2005-06-20 WO PCT/US2005/021812 patent/WO2006002097A2/en not_active Ceased
- 2005-06-20 CA CA2571049A patent/CA2571049C/en not_active Expired - Fee Related
- 2005-06-20 CA CA2931917A patent/CA2931917A1/en not_active Abandoned
- 2005-06-20 MX MX2012003410A patent/MX359668B/es unknown
- 2005-06-20 ES ES11163943.1T patent/ES2644981T3/es not_active Expired - Lifetime
- 2005-06-20 PT PT57735763T patent/PT1765322E/pt unknown
- 2005-06-20 US US11/629,875 patent/US7951841B2/en active Active
- 2005-06-20 PT PT111639472T patent/PT2397133T/pt unknown
- 2005-06-20 NZ NZ587006A patent/NZ587006A/en not_active IP Right Cessation
- 2005-06-20 SI SI200531827T patent/SI1765322T1/sl unknown
- 2005-06-20 ES ES11163947.2T patent/ES2644984T3/es not_active Expired - Lifetime
- 2005-06-20 ES ES05773576.3T patent/ES2443194T3/es not_active Expired - Lifetime
- 2005-06-20 KR KR1020127013912A patent/KR101323122B1/ko not_active Expired - Fee Related
- 2005-06-20 RU RU2010138410/04A patent/RU2554003C2/ru active
- 2005-06-20 NZ NZ552080A patent/NZ552080A/en not_active IP Right Cessation
- 2005-06-20 IN IN9335DEN2012 patent/IN2012DN09335A/en unknown
- 2005-06-20 CN CN201210458886.5A patent/CN102976937B/zh not_active Expired - Fee Related
- 2005-06-20 JP JP2007516822A patent/JP5166026B2/ja not_active Expired - Fee Related
- 2005-06-20 AU AU2005257997A patent/AU2005257997B2/en not_active Ceased
- 2005-06-20 HU HUE11163947A patent/HUE036596T2/hu unknown
- 2005-06-20 PL PL11163947T patent/PL2397133T3/pl unknown
2006
- 2006-12-14 IL IL180078A patent/IL180078A/en active IP Right Grant
2007
- 2007-01-17 NO NO20070330A patent/NO339969B1/no not_active IP Right Cessation
2011
- 2011-03-07 US US13/042,308 patent/US9174936B2/en not_active Expired - Lifetime
2012
- 2012-06-28 JP JP2012145562A patent/JP5596749B2/ja not_active Expired - Fee Related
- 2012-09-14 US US13/619,887 patent/US9388130B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/619,945 patent/US9403765B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/619,731 patent/US9169204B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/619,631 patent/US9162978B2/en not_active Expired - Lifetime
- 2012-10-11 IL IL222347A patent/IL222347A/en active IP Right Grant
2013
- 2013-12-30 IL IL230242A patent/IL230242A/en active IP Right Grant
- 2013-12-30 IL IL230241A patent/IL230241A/en active IP Right Grant
2014
- 2014-02-05 CY CY20141100096T patent/CY1114873T1/el unknown
2016
- 2016-07-19 US US15/214,330 patent/US10117845B2/en not_active Expired - Lifetime
2017
- 2017-10-18 CY CY20171101089T patent/CY1119480T1/el unknown
2018
- 2018-10-31 US US16/177,076 patent/US20190167626A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ587006A (en)	2011-12-22
KR20130079669A (ko)	2013-07-10
US9169204B2 (en)	2015-10-27
EP2397130B1 (de)	2019-04-03
JP2012229234A (ja)	2012-11-22
ES2644984T3 (es)	2017-12-01
DK2397133T3 (en)	2017-10-30
US9388130B2 (en)	2016-07-12
CA2931917A1 (en)	2006-01-05
EP2397131A2 (de)	2011-12-21
JP5596749B2 (ja)	2014-09-24
IL230242A (en)	2015-10-29
ES2644981T3 (es)	2017-12-01
HUE036596T2 (hu)	2018-07-30
PT2397133T (pt)	2017-10-23
EP2397132A3 (de)	2012-07-11
BRPI0511396A (pt)	2007-12-04
ZA200700368B (en)	2008-10-29
US20190167626A1 (en)	2019-06-06
EP2397133A3 (de)	2012-07-11
HK1098696A1 (en)	2007-07-27
CY1114873T1 (el)	2016-12-14
EP2397131B1 (de)	2019-09-11
US7951841B2 (en)	2011-05-31
IL180078A (en)	2014-01-30
EP2397130A2 (de)	2011-12-21
EP2397133A2 (de)	2011-12-21
US9403765B2 (en)	2016-08-02
US20110288170A1 (en)	2011-11-24
SI1765322T1 (sl)	2014-03-31
US20130072556A1 (en)	2013-03-21
EP2397133B1 (de)	2017-07-26
LT2397133T (lt)	2018-01-10
IL222347A (en)	2017-08-31
EP1765322A2 (de)	2007-03-28
US9162978B2 (en)	2015-10-20
KR101323122B1 (ko)	2013-10-30
PL2397133T3 (pl)	2018-01-31
MXPA06014750A (es)	2007-03-21
US10117845B2 (en)	2018-11-06
CN1988898A (zh)	2007-06-27
NZ552080A (en)	2011-03-31
US9174936B2 (en)	2015-11-03
WO2006002097A2 (en)	2006-01-05
CY1119480T1 (el)	2018-03-07
EP2397132A2 (de)	2011-12-21
US20130072559A1 (en)	2013-03-21
CN102976937A (zh)	2013-03-20
RU2408578C2 (ru)	2011-01-10
CN1988898B (zh)	2012-12-26
KR101490145B1 (ko)	2015-02-05
KR20070026817A (ko)	2007-03-08
ES2443194T3 (es)	2014-02-18
US20130072560A1 (en)	2013-03-21
KR101337321B1 (ko)	2013-12-06
KR20120062946A (ko)	2012-06-14
IL230241A (en)	2015-06-30
PT1765322E (pt)	2014-02-05
JP5166026B2 (ja)	2013-03-21
NO339969B1 (no)	2017-02-20
EP2397130A3 (de)	2012-10-31
WO2006002097A3 (en)	2006-05-04
AU2005257997B2 (en)	2012-04-05
RS53178B (sr)	2014-06-30
NO20070330L (no)	2007-03-15
EP1765322A4 (de)	2008-09-17
PL1765322T3 (pl)	2014-04-30
ES2752924T3 (es)	2020-04-06
BRPI0511396B1 (pt)	2021-07-27
EP1765322B1 (de)	2013-11-06
AU2005257997A1 (en)	2006-01-05
SI2397133T1 (sl)	2017-12-29
IL180078A0 (en)	2007-05-15
JP2008503496A (ja)	2008-02-07
CA2571049A1 (en)	2006-01-05
HRP20140116T1 (hr)	2014-03-28
EP2397131A3 (de)	2012-10-31
MX359668B (es)	2018-10-05
KR20140140616A (ko)	2014-12-09
RU2010138410A (ru)	2012-03-27
US20170014368A1 (en)	2017-01-19
RU2554003C2 (ru)	2015-06-20
RU2007101735A (ru)	2008-07-27
CN102976937B (zh)	2016-12-21
CA2571049C (en)	2016-08-09
EP2397132B1 (de)	2017-07-26
DK1765322T3 (da)	2014-02-10
US20130079403A1 (en)	2013-03-28
US20080221208A1 (en)	2008-09-11

Publication	Publication Date	Title
IN2012DN09335A (de)	2015-08-21
WO2004082622A3 (en)	2005-02-24	Retinoid replacements and opsin agonists and methods for the use thereof
MX2010001754A (es)	2010-05-14	Derivados de azepina como inhibidores de gamma secretasa.
SG173374A1 (en)	2011-08-29	Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
AU2016204344A1 (en)	2016-07-14	Improved methods and compositions for wound healing
MX2010006736A (es)	2010-10-15	Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MY151455A (en)	2014-05-30	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
PH12012501346A1 (en)	2012-12-17	Heteroaryl compounds and uses thereof
WO2011084803A3 (en)	2011-11-24	Coloring agents and methods of use thereof
MY173526A (en)	2020-01-31	Novel anti-?5?1 antibodies and uses thereof
MX359639B (es)	2018-10-04	Metodos y composiciones para uso en tratamientos celulares.
MX2009013982A (es)	2010-04-09	Composiciones que comprenden inhibidores de triptofano hidroxilasa.
TW200624426A (en)	2006-07-16	BACE inhibitors
SG148179A1 (en)	2008-12-31	Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
IN2012DN03844A (de)	2015-08-28
MX2008001538A (es)	2008-04-04	Aril piridinas y metodos para su uso.
MY162181A (en)	2017-05-31	Compositions and methods for modulating hemostasis
UY30801A1 (es)	2008-07-03	Compuestos calciliticos
SG149831A1 (en)	2009-02-27	Benzimidazole derivatives
TW200734306A (en)	2007-09-16	Novel compounds, their preparation and use
MX2007002277A (es)	2007-07-10	Metodos para formar retinoides y usos de los mismos.
MX2007002917A (es)	2007-07-11	Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
UY29434A1 (es)	2006-10-02	Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
SV2010003755A (es)	2011-03-15	Nuevos derivados de (piperazinilo con enlaces puente)-1-alcanona y su utilizacion como inhibidores de p75
AU2009235634A8 (en)	2013-05-23	Substituted sulfonamide derivatives